ECOG-ACRIN EA6134

Primary Category:

Treatment Protocols

Disease Category:

Melanoma, Metastatic Melanoma, Skin

Status:

Open

A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Eligible for screening study DCP 001

NCT#02224781